2 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
20 Oct 16
Other Events
12:00am
COMPANY 18
19 PEPVAX FOR POST - ASCT ( HELOCYTE ) Antigen target applicable to ~35% of Patients Healthy volunteer Phase 1 completed - Safe, well … % of Patients CMV MVA DNA Vaccine (pp65, IE1, IE2) HEALTHY VOLUNTEER PHASE 1 PRESENTED AT ASH 2015 Phase 2 (Enrolling As Of 11/2015) Safe, well tolerated
10-12G
EX-10
CKPT
Checkpoint Therapeutics Inc
11 Jul 16
Registration of securities
12:00am
tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteer.
1.61 “Phase II
- Prev
- 1
- Next